4-[4]Pyridylamino-phenol | 82564-31-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[4]Pyridylamino-phenol
• 英文别名: 4-(pyridin-4-ylamino)phenol；4-(4-Pyridylamino)phenol
• CAS: 82564-31-6
• 化学式: C₁₁H₁₀N₂O
• 分子量: 186.213
• InChiKey: JHOUAJWDARLISP-UHFFFAOYSA-N

物化性质

• 熔点：
  236-237 °C
• 沸点：
  357.9±17.0 °C(Predicted)
• 密度：
  1.265±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  四氢吡咯 、 聚合甲醛 、 4-[4]Pyridylamino-phenol 以 乙醇 为溶剂， 反应 3.0h， 生成 4-<3,5-bis<(N-pyrrolidinyl)methyl>-4-hydroxyanilino>pyridine
  参考文献：
  名称：

  Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 1. Heteroarylamine derivatives

  摘要：

  Twenty-four structural derivatives of the antiarrhythmic drug changrolin were synthesized and tested for antiarrhythmic and parasympatholytic activities. It was found that while the bis(pyrrolidinylmethyl)phenol pattern of changrolin appeared to be optimal in this series, a wide latitude existed for the heteroaryl substituent for maintaining good antiarrhythmic activity. Further, the antiarrhythmic and parasympatholytic activities tended to exhibit parallel changes.

  DOI：

  10.1021/jm00360a005
• 作为产物：
  描述：

  4-氯吡啶 、 对氨基苯酚 以 乙醇 为溶剂， 反应 2.0h， 生成 4-[4]Pyridylamino-phenol
  参考文献：
  名称：

  Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 1. Heteroarylamine derivatives

  摘要：

  Twenty-four structural derivatives of the antiarrhythmic drug changrolin were synthesized and tested for antiarrhythmic and parasympatholytic activities. It was found that while the bis(pyrrolidinylmethyl)phenol pattern of changrolin appeared to be optimal in this series, a wide latitude existed for the heteroaryl substituent for maintaining good antiarrhythmic activity. Further, the antiarrhythmic and parasympatholytic activities tended to exhibit parallel changes.

  DOI：

  10.1021/jm00360a005

文献信息

• INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20160176848A1

  公开（公告）日：2016-06-23

  Compounds of formula (I) wherein Ra, Rb, Rc, Rd, T, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)中的化合物，其中Ra、Rb、Rc、Rd、T、R3、R4、R5、X、Y和Het的定义如描述中所述。 包含这些化合物的药物产品，对于治疗涉及凋亡缺陷的病理情况，如癌症、自身免疫疾病和免疫系统疾病非常有用。
• PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20150031673A1

  公开（公告）日：2015-01-29

  Compounds of formula (I): wherein A 1 , A 2 , R a , R b , R c , R d , R 3 , R 4 , R 5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)的化合物： 其中A 1 ，A 2 ，R a ，R b ，R c ，R d ，R 3 ，R 4 ，R 5 和T的定义如描述中所述。 含有这些化合物的药物产品对于治疗涉及凋亡缺陷的病理，如癌症、自身免疫疾病和免疫系统疾病，具有益处。
• INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20160152599A1

  公开（公告）日：2016-06-02

  Compounds of formula (I): wherein R a , R b , R c , R d , R 3 , R 4 , R 5 , A 1 , A 2 , T and W are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式（I）的化合物：其中Ra、Rb、Rc、Rd、R3、R4、R5、A1、A2、T和W的定义如描述中所述。含有这些化合物的药品对治疗涉及凋亡缺陷的病理病变，如癌症、自身免疫疾病和免疫系统疾病等，具有益处。
• PHOSPHATE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20150031648A1

  公开（公告）日：2015-01-29

  Compounds of formula (I): wherein X, Y, A 1 , A 2 , R a , R b , R c , R d , R 3 , R 4 , T and R 5 are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)的化合物：其中X、Y、A1、A2、Ra、Rb、Rc、Rd、R3、R4、T和R5的定义如描述中所示。包含这些化合物的药物制剂对于治疗涉及凋亡缺陷的病理，如癌症、自身免疫疾病和免疫系统疾病，具有益处。
• Heterocyclic derivatives
  申请人：Zeneca Limited

  公开号：US05652242A1

  公开（公告）日：1997-07-29

  Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Novel intermediates are also disclosed.

  式I的化合物以及其代谢易变酯和酰胺，以及药学上可接受的盐，其中R.sup.13、M.sup.2、X.sup.1、Z.sup.1、Z.sup.1a、X.sup.2和A.sup.1的含义如规范中所述。该化合物可用作抑制纤维蛋白原与糖蛋白IIb/IIIa结合的抑制剂。还公开了新的中间体。